Sanofi Enters into Agreement to Acquire Blueprint Medicines
The proposed acquisition will expand Sanofi’s immunological portfolio with a precision medicine already approved for the treatment of ASM and ISM, a next-gen highly selective kinase inhibitor, and an investigational oral drug.
R&D driven biopharma company, Sanofi, has announced that it has entered into an agreement to acquire U.S.-based, publicly traded biopharma company, Blueprint Medicines Corporation for approximately USD 9.5 billion. The proposed acquisition, which was revealed by Sanofi in a June 2, 2025 press release, will include Blueprint’s rare immunology disease medicine, avapritinib (Ayvakit/Ayvakyt) (1).
Avapritinib is a precision medicine that has gained regulatory approval from the FDA and EMA for the treatment of advanced and indolent systemic mastocytosis (ASM and ISM) (2–5), making it the only approved therapy for these indications in the U.S. ad E.U. ASM and ISM are characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs, that can cause severe symptoms in patients. Avapritinib has been designed to potently and selectively target the primary underlying driver of the disease, KIT D816V.
“The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company,” said Paul Hudson, CEO, Sanofi, in the press release (1). “This acquisition is fully aligned with our strategic intent to strengthen our existing therapeutic areas, to bring relevant and differentiated medicines to patients and to secure attractive returns to our shareholders. It complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions. We are excited to welcome Blueprint’s talented people and we look forward to chasing the miracles of science together. This makes sense for science, for both companies, for healthcare professionals, and — most of all — for patients.”
“Since our founding, Blueprint Medicines has worked at the intersection of scientific innovation and operational excellence. I’m incredibly proud of the medical innovations our people have created and delivered to patients. We have translated our unique scientific understanding of mast cell biology into a portfolio of important therapies including Ayvakit — the first and only medicine approved to treat the root cause of systemic mastocytosis — and worked collaboratively with communities to improve standards of care and patient outcomes,” added Kate Haviland, CEO, Blueprint Medicines, in the press release (1). “With this agreement, we begin our next chapter with Sanofi, whose exceptional leadership in rare disease and immunology and proven ability to solve medical challenges at scale stand to accelerate our joint mission to bring life-changing medicines to many more patients around the world.”
Additionally, under the terms of the agreement, Sanofi will gain Blueprint’s elenestinib — a next-generation medicine for SM — and BLU-808 — a highly selective and potent oral wild-type KIT inhibitor, which has potential as a treatment for a broad range of immunological diseases.
References
Sanofi. Sanofi to Acquire Blueprint Medicines, Expanding Portfolio in Rare Immunological Disease and Adding Early-Stage Pipeline in Immunology. Press Release, June 2, 2025.
Blueprint Medicines. FDA Approves Blueprint Medicines’ AYVAKIT (Avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis. Press Release, June 16, 2021.
Blueprint Medicines. Blueprint Medicines’ AYVAKYT (Avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis. Press Release, March 25, 2022.
Blueprint Medicines. FDA Approves AYVAKIT (Avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis. Press Release, May 22, 2023.
Blueprint Medicines. Blueprint Medicines' AYVAKYT (Avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis. Press Release, Dec. 12, 2023.